For the year ending 2025-12-31, NXTC had -$1,745K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -55,844 |
| Depreciation and amortization | 2,185 |
| Amortization of premiums and discounts on marketable securities | 481 |
| Stock-based compensation | 2,986 |
| Noncash operating lease expense | 587 |
| Prepaid expenses and other assets | -1,102 |
| Accounts payable | -3,342 |
| Accrued liabilities and other liabilities | -4,334 |
| Lease liabilities | -1,005 |
| Other long-term liabilities | -135 |
| Net cash used in operating activities | -49,613 |
| Sales and maturities of marketable securities | 52,261 |
| Purchases of marketable securities | 26,705 |
| Net cash provided by investing activities | 25,556 |
| Proceeds from issuance of common stock | 22,276 |
| Proceeds from shares issued under espp | 36 |
| Net cash provided by financing activities | 22,312 |
| Net increase (decrease) in cash and cash equivalents | -1,745 |
| Cash and cash equivalents - beginning of period | 27,727 |
| Cash and cash equivalents - end of period | 25,982 |
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)